Highlights

  • Alterity Therapeutics (ASX:ATH) continues preparations for a Phase 3 ATH434 study.
  • FDA meeting minutes confirmed alignment on key elements of the proposed trial.
  • September-quarter cash totalled AUD 41.3 million, including financing and tax receipts.
  • A new US Patent covering an ATH434 formulation extends to 2045.

Alterity Therapeutics Limited develops investigational treatments for neurodegenerative diseases, with its ATH434 drug programme focused on multiple system atrophy (MSA). On 13 November 2026, Alterity Therapeutics (ASX:ATH) was trading at AUD 0.245, down 2.00% for the session. The company's latest operational disclosures describe preparations for a pivotal study following discussions with US regulators, additional intellectual-property protection and its financial position at the end of September.

ATH434 and the Multiple System Atrophy Programme

Alterity (ASX:ATH) is a clinical-stage biotechnology Business focused on neurological disorders. Its lead compound, ATH434, is being developed as a potential disease-modifying treatment for MSA, a progressive condition affecting movement and autonomic functions. The proposed therapeutic approach concerns abnormal iron handling and protein-related processes associated with neurological disease. Clinical development remains necessary to establish efficacy and safety for regulatory purposes.

The company also studies potential applications of ATH434 in Parkinson's disease. In August 2026, a US composition-of-matter patent was granted for a crystalline form of its mesylate salt, which the company said was used in Phase 2 studies and is planned for its Phase 3 programme. Patent protection is stated to extend to 2045; that protection is distinct from any regulatory authorisation to market the drug.

Regulatory Update and Study Preparation

In its October quarterly activities report, Alterity stated that final minutes of its US Food and Drug Administration End-of-Phase 2 meeting confirmed agreement on the proposed study population, dose regimen and principal outcome measure. The intended primary endpoint is the 11-item Unified Multiple System Atrophy Rating Scale Part I, assessing activities of daily living. Key secondary endpoints were also discussed.

The proposed Phase 3 study is expected to recruit approximately 200 participants, allocated equally between ATH434 at 50 milligrams twice daily and placebo for 12 months. The regulator indicated that one pivotal trial alongside confirmatory evidence could support a potential approval submission; this is not an assurance of approval. Alterity identified its Phase 2 ATH434-201 data as expected supporting evidence.

Work already underway includes protocol finalisation, vendor selection, clinical-site qualification and Manufacturing the first registration batch. On 12 November, the company also announced that its chief executive, David Stamler, would present at a virtual healthcare conference on 19 November 2026.

Financial Position and Development Context

Alterity (ASX:ATH) reported AUD 41.3 million in cash as at 30 September 2026. That balance included an AUD 3.98 million Australian research-and-development tax incentive refund and approximately AUD 5.5 million of net proceeds from exercises of listed ATHO options. These financing and tax items are relevant when evaluating available funding; they should not be confused with Revenue generated by an approved medicine.

Trial start-up, recruitment and manufacturing require funding before potential product sales. Costs can change with trial scope and timing.

Risks and Operational Milestones

MSA is a challenging clinical indication, and progress from an earlier study does not establish the outcome of a pivotal trial. Recruitment delays, variability in patient responses, manufacturing issues, regulatory requests and the availability of funding could all affect execution. The company has said it continues to evaluate strategic funding and partnering alternatives for Phase 3 development.

Near-term points to monitor include trial-site activation, initiation of recruitment, confirmation of the final protocol and subsequent cash-flow reporting. Intellectual-property coverage and scientific publications add context but do not replace clinical efficacy evidence.

Key Insights

Alterity (ASX:ATH) has moved its ATH434 programme into Phase 3 operational preparation after discussions with the FDA. Its September cash position and recent patent grant provide financial and intellectual-property context. The timetable for study initiation, enrolment and future regulatory assessments remains central to subsequent company updates.